Skin News

Wednesday, January 16, 2008 Etanercept Clears Plaque Psoriasis in Children and Adolescents
Etanercept (Enbrel®) safely reduces disease severity in children and adolescents with moderate-to-severe plaque psoriasis, and improvements are evident as early as the second week of therapy...

Tuesday, January 15, 2008 Three More Cases of Significant Neutropenia Lead to Recommendation for Routine CBC Monitoring
Three more cases of significant neutropenia in rheumatoid arthritis (RA) and psoriatic arthritis patients treated with etanercept lead to a recommendation for regular monitoring of complete blood counts (CBC)...

Tuesday, January 08, 2008 Tacrolimus in Dermatology—Pharmacokinetics, Mechanism of Action, Drug Interactions, Dosages, and Side Effects
Researchers have assessed the efficacy and safety of tacrolimus treatment in dermatology...

Monday, January 07, 2008 Abbott's Humira® Approved in the EU for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott announced it has received marketing authorization from the European Commission for the use of the TNF antagonist Humira® (adalimumab) as a treatment for moderate-to-severe plaque psoriasis. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis...

Thursday, December 06, 2007  Drug Update: Rituximab
Repeat rituximab was notably effective in patients with DMARD-resistant RA, and the B-cell depleting agent is being tested in pediatric SLE and in Sjögren's syndrome...

Wednesday, December 05, 2007 Drug Update: Infliximab
Researchers offer advice on reducing infliximab infusion times in RA, predicting who will respond, and what to expect in patients with ankylosing spondylitis...

Tuesday, November 20, 2007 Abbott's Humira® Receives Positive Opinion From EMEA for Treatment of Moderate-to-Severe Plaque Psoriasis 
Abbott Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP), granted Abbott a positive opinion recommending approval of Humira® (adalimumab) for the treatment of moderate-to-severe plaque psoriasis...

Wednesday, November 14, 2007 Fish Oil May Improve Symptoms and Endothelial Function in SLE
Omega-3 fish oil may reduce lupus disease activity and improve endothelial function...

Tuesday, November 13, 2007 Anti-IL-12/23 Monoclonal Produces Dramatic Results in Psoriatic Arthritis
The anti-IL-12/23 monoclonal antibody ustekinumab produced dramatic, durable improvements in psoriatic arthritis, according to phase II data reported at the American College of Rheumatology...

Friday, November 09, 2007 Efalizumab Suspected of Triggering Arthritis in Subset of Psoriasis Patients
A small subset of patients treated with efalizumab for severe plaque psoriasis developed new-onset psoriatic arthritis...